Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- Miraka HD: Sales Up 11.2% with Addition of New Subsidiaries
June 27, 2011
- Nycomed Takes Over Bisphosphonate from Roche
June 27, 2011
- Takeda to Start PIII Trial for Hib Vaccine
June 27, 2011
- Eiken: Sales Up 2.7% Driven by Extraordinary Demand due to Disaster
June 27, 2011
- NanoCarrier to Obtain Substance Patent for pH-Responsive Micelles
June 27, 2011
- Otsuka to Start PI for Cancer Vaccine OCV-105 in Japan
June 27, 2011
- Takara Bio: Sales Down 3.0% due to Decline in Sales of Scientific Instruments
June 27, 2011
- Call For “Copayment Revision”Remains Unchanged in Revised SS Reform Plan
June 27, 2011
- NCC, Shimadzu Tie Up to Develop Advanced Cancer Treatment Technology
June 27, 2011
- Takeda Sues 18 Generic Companies for Actos Patent Infringement
June 27, 2011
- Compassionate Use of Unapproved Drugs to Require Clarification of Roles, Responsibilities
June 27, 2011
- Sangi Develops Oral Formulation for Cisplatin
June 27, 2011
- Taiyo's Acquisition by Teva Provides New Opportunity for GE Ind.: Mr Honda of Mylan
June 27, 2011
- FDA Issues Warning on Bladder Cancer Risk Associated with Actos
June 27, 2011
- Pfizer to Conduct First-ever “Virtual Clinical Trial”
June 27, 2011
- Do Practice and Experience Maketh the Marketer?
June 27, 2011
- Korosho to Promptly Assess Bladder Cancer Risk due to Actos
June 27, 2011
- Dacogen Increases OS in AML Patients: Eisai
June 27, 2011
- Aratani Family Excluded from Teva-Controlled Taiyo
June 27, 2011
- Novartis, Ono to Promote Rivastigmine Stressing Its Beneficial Effects on ADL
June 27, 2011
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…